Halo Pharma is part of the Noramco Group, which is a leading provider of pharmaceutical services, including API, contract dosage form development, commercial manufacturing and analytical services. Together with our sister companies, Purisys LLC and Noramco LLC, we offer full end to end CDMO services from API development including NCEs & DEA Schedule I compounds such as psilocybin & MDMA, process development and optimization, through all stages of clinical and bulk commercialization to drug product development and manufacturing. Halo Pharma serves a growing global customer base across multiple regulatory environments including but not limited to FDA, Health Canada, MHRA, EDQM and ANVISA.

Type of Drugs Manufactured:

Small Molecule

CDMO Services:

Drug Substance Manufacturing (API);Drug Product Formulation (FDF);Packaging;Analytical Development

No. of Manufacturing Facilities:

3-5

 High Potent Products capabilities:

OEB 3

Facilities Locations:

North America

Regulatory Approvals for facilities:

FDA (United States);EMA (Europe);GMP;Health Canada;ANVISA (Brazil)

Manufacturing Technologies:

Liquids;Semi-solids;Solids